Jasper Therapeutics
JSPR
56 hedge funds and large institutions have $83.7M invested in Jasper Therapeutics in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
8% more funds holding
Funds holding: 52 → 56 (+4)
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
0.04% less ownership
Funds ownership: 84.23% → 84.19% (-0.04%)
0% less capital inflows, than outflows
Capital inflows: $22.8M | Capital outflows: $22.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$4.35M |
| 2 |
Mizuho Securities USA
New York
|
+$3.93M |
| 3 |
Kohlberg Kravis Roberts & Co
New York
|
+$3.25M |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.99M |
| 5 |
B. Riley Financial
Los Angeles,
California
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Glazer Capital LLC
New York
|
-$9.8M |
| 2 |
Sage Rock Capital Management
New York
|
-$4.59M |
| 3 |
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$2.73M |
| 4 |
Mangrove Partners
Greenwich,
Connecticut
|
-$2.08M |
| 5 |
Linden Advisors
New York
|
-$1.27M |
JSPR Hedge Fund Activity: Q2 2021 in Review
56 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q2 2021, worth a combined $83.7M — up 0.25% from $83.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new JSPR positions and 4 closed out — a net gain of 4 holders — while 14 added to existing stakes and 14 trimmed.
The largest buyer was W.R. Berkley Corp, opening a new position worth an estimated $4.35M. The largest seller was Glazer Capital LLC, cutting an estimated $9.8M.
- 56 institutional investors held Jasper Therapeutics (JSPR) as of Q2 2021, up from 52 in Q1 2021.
- Funds reported $83.7M of Jasper Therapeutics stock for Q2 2021, up 0.25% quarter-over-quarter.
- 8 funds opened new Jasper Therapeutics positions in Q2 2021 and 4 closed out, a net change of +4 holders.
- The largest Jasper Therapeutics buyer in Q2 2021 was W.R. Berkley Corp, an estimated $4.35M added.
- The largest Jasper Therapeutics seller in Q2 2021 was Glazer Capital LLC, an estimated $9.8M sold.
Based on aggregated 13F filings for Q2 2021.